scholarly journals Clinical Efficacy and Safety Profile of Prucalopride in Chronic Idiopathic Constipation

Cureus ◽  
2019 ◽  
Author(s):  
Asim Tameez Ud Din ◽  
Ameer H Khan ◽  
Hamza Bajwa ◽  
Muhammad Haisum Maqsood ◽  
Mustafa N Malik
Keyword(s):  
Clinical Efficacy ◽  
Safety Profile ◽  
Efficacy And Safety ◽  
Idiopathic Constipation ◽  
Chronic Idiopathic Constipation

Sa1440 A Phase III Study of the Efficacy and Safety of Plecanatide in the Treatment of Chronic Idiopathic Constipation (CIC) (Study-00)

2016 ◽  
Vol 150 (4) ◽  
pp. S316 ◽  
Author(s):  
Philip B. Miner ◽  
Blas Prieto ◽  
Marianela De La Portilla ◽  
William Koltun ◽  
Mary Beth Layton ◽  
...  
Keyword(s):  
Phase Iii ◽  
Efficacy And Safety ◽  
Idiopathic Constipation ◽  
Chronic Idiopathic Constipation ◽  
Phase Iii Study

Clinical efficacy and safety following dose tapering of ciclosporin in cats with hypersensitivity dermatitis

2016 ◽  
Vol 18 (11) ◽  
pp. 898-905 ◽  
Author(s):  
Elizabeth S Roberts ◽  
Tiffany Tapp ◽  
Ann Trimmer ◽  
Linda Roycroft ◽  
Stephen King
Keyword(s):  
Adverse Events ◽  
Clinical Response ◽  
Clinical Efficacy ◽  
Safety Profile ◽  
Therapeutic Response ◽  
Clinical Pathology ◽  
Efficacy And Safety ◽  
Dosing Frequency ◽  
Dosing Regimens ◽  
Physical Examinations

Objectives This study was designed to evaluate the efficacy and safety of reducing ciclosporin (CsA) dosing frequency from daily to every other day (EOD) or twice a week (TW) according to clinical response in cats with hypersensitivity dermatitis (HD) and treated with CsA. Methods One hundred and ninety-one cats with HD were given 7 mg/kg CsA daily for at least 4 weeks. Depending on clinical response, the dosing frequency was tapered from daily to EOD over the next 4 weeks and further to TW for an additional 4 weeks. Safety was evaluated through physical examinations, clinical pathology and the monitoring of adverse events (AEs). Results The majority of cats were able to have their dose of CsA tapered to either EOD (15.5%) or TW (62.9%) according to the clinical response. Observed AEs were most frequently mild and self-limiting vomiting and diarrhea. A higher percentage of AEs occurred with daily administration (73%) compared with other dosing regimens (27%). Conclusions and relevance Following 4 weeks of daily dosing at 7 mg/kg, CsA may be tapered to EOD or TW while maintaining the desired therapeutic response in cats with HD. Additionally, CsA appears to be well tolerated with fewer AEs at EOD or TW dosing. Establishing the lowest effective dosing frequency of CsA improves the drug’s safety profile.

Su1214 Efficacy and Safety of Plecanatide in the Treatment of Chronic Idiopathic Constipation (CIC): Results From a Multicenter Phase III Study (Study-03)

2016 ◽  
Vol 150 (4) ◽  
pp. S497-S498 ◽  
Author(s):  
Philip B. Miner ◽  
John David Lentz ◽  
Ramon Berenguer ◽  
Maria Nualart ◽  
Bernadette Hickey ◽  
...  
Keyword(s):  
Phase Iii ◽  
Efficacy And Safety ◽  
Idiopathic Constipation ◽  
Chronic Idiopathic Constipation ◽  
Multicenter Phase ◽  
Phase Iii Study

scholarly journals A RANDOMIZED ACTIVE CONTROLLED CLINICAL STUDY TO EVALUATE EFFICACY AND SAFETY OF RESVERATROL AS AN ADJUVANT THERAPY IN PATIENTS WITH HYPERTENSION

2016 ◽  
Vol 10 (1) ◽  
pp. 376
Author(s):  
Rakesh Ojha ◽  
Kulkarni Pranesh ◽  
Vyas Bhavin
Keyword(s):  
Essential Hypertension ◽  
Adjuvant Therapy ◽  
Clinical Efficacy ◽  
Safety Profile ◽  
Gold Standard ◽  
Standard Therapy ◽  
Controlled Study ◽  
Efficacy And Safety ◽  
Hypertensive Patients

ABSTRACTObjectives: No long-term clinical efficacy and safety study of resveratrol as adjuvant therapy along with gold standard therapy has been conductedin patients with essential hypertension. The aim of this study was to investigate the efficacy and safety of resveratrol as an adjuvant therapy in newlydiagnosed hypertensive patients.Methods: In this randomized active-controlled study, hypertensive patients (male/female) of 20-65 years aged were randomized (1:1) to receivetelmisartan 20 mg or telmisartan 20 mg plus resveratrol 1 g daily for 12 months. Efficacy variables included a change in systolic and diastolic bloodpressure (DBP) from baseline and were followed up for every 3 months. Treatment-emergent adverse events were assessed.Results: A total of 60 hypertensive patients were analyzed (telmisartan [n=30] and telmisartan plus resveratrol [n=30]). Resveratrol as an adjuvantwith telmisartan significantly reduced in systolic (p<0.001) and DBP (p<0.001) as compared to telmisartan monotherapy. Change in systolic and DBPfrom baseline was significantly higher in telmisartan plus resveratrol group than telmisartan (p<0.001) at all followed visits. Both the study drugshave similar safety profile and found well tolerable.Conclusions: Resveratrol plus Telmisartan was found to be superior over telmisartan monotherapy in reducing systolic and DBP in newly diagnosedhypertensive patients. Both the study drugs were effective with comparable safety profile. Our study supports the long-term clinical efficacy andsafety study of resveratrol along with gold standard therapy in essential hypertension.Keywords: Essential hypertension, Resveratrol, Systolic and diastolic blood pressure, Telmisartan.

Sign in / Sign up

Export Citation Format

Share Document